Hydrocodone

CHEMBL1457 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

299.4 g/mol

LogP

2.2

Phase

4

An opioid pain reliever and cough suppressant used to treat moderate to severe pain and to suppress chronic cough, working by binding to opioid receptors in the brain and spinal cord to alter the perception of pain. It is typically formulated in combination with acetaminophen or other non-opioid analgesics. Due to its high potential for dependence and abuse, it is a Schedule II controlled substance requiring careful prescribing.

Berat Molekul

299,4000 g/mol

LogP

2,20

TPSA

38,80 Å²

Lipinski RO5

Lulus

Area Terapeutik

Pain Management Obesity Lymphoma Breast Cancer Chronic Pain

Mekanisme Kerja

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314

InChI

InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1

Molecular Formula

C18H21NO3

HBD / HBA

- / 4

Ikatan yang Dapat Dirotasi

1

Atom Berat

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

An opioid pain reliever and cough suppressant used to treat moderate to severe pain and to suppress chronic cough, working by binding to opioid receptors in the brain and spinal cord to alter the perception of pain. It is typically formulated in combination with acetaminophen or other non-opioid analgesics. Due to its high potential for dependence and abuse, it is a Schedule II controlled substance requiring careful prescribing.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Hydrocodone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1457. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5284569. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Mencari informasi yang ramah bagi pasien?

Hydrocodone di PillFYI

Struktur

Data Cepat

Rumus: C18H21NO3
Sinonim: 23

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.